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Summary
Background The injectable hormonal contraceptive depo-medroxyprogesterone acetate (DMPA) has been associated 
with increased risk of HIV acquisition, but ﬁ ndings are inconsistent. Whether DMPA increases the risk of other 
sexually transmitted viral infections is unknown. We assessed the association between DMPA use and incident 
herpes simplex virus type 2 (HSV2) infection in women.
Methods In this prospective study, we enrolled HIV-negative and HSV2-negative women aged 15–49 years whose 
HIV-negative male partners were concurrently enrolled in a randomised trial of male circumcision in Rakai, Uganda. 
We excluded women if either they or their male partners HIV seroconverted. The primary outcome was HSV2 
seroconversion, assessed annually. The male circumcision trial was registered with ClinicalTrials.gov, number 
NCT00425984.
Findings Between Aug 11, 2003, and July 6, 2006, we enrolled 682 women in this study. We noted HSV2 
seroconversions in 70 (10%) women. Incidence was 13·5 per 100 person-years in women consistently using DMPA 
(nine incident infections per 66·5 person-years), 4·3 per 100 person-years in pregnant women who were not using 
hormonal contraception (18 incident infections per 423·5 person-years), and 6·6 per 100 person-years in women 
who were neither pregnant nor using hormonal contraception (35 incident infections per 529·5 person-years). 
Women consistently using DMPA had an adjusted hazard ratio for HSV2 seroconversion of 2·26 (95% CI 
1·09–4·69; p=0·029) compared with women who were neither pregnant nor using hormonal contraception. Of 
132 women with HSV2-seropositive partners, seroconversion was 36·4 per 100 person-years in consistent DMPA 
users (four incident infections per 11 person-years) and 10·7 per 100 person-years in women who were neither 
pregnant nor using hormonal contraception (11 incident infections per 103 person-years; adjusted hazard ratio 
6·23, 95% CI 1·49–26·3; p=0·012).
Interpretation Consistent DMPA use might increase risk of HSV2 seroconversion; however, study power was low. 
These ﬁ ndings should be assessed in larger populations with more frequent follow-up than in this study, and other 
contraceptive methods should also be assessed. Access to a wide range of highly eﬀ ective contraceptive methods is 
needed for women, particularly in sub-Saharan Africa.
Funding Bill and Melinda Gates Foundation, Doris Duke Charitable Foundation, US National Institutes of Health, 
and Fogarty International Center.
Copyright © Grabowski et al. Open Access article distributed under the terms of CC BY-NC-ND.
Introduction
Hormonal contraceptive use is becoming increasingly 
common in sub-Saharan Africa,1 and long-acting 
injectable hormonal contraceptives are some of the most 
eﬀ ective and frequent contraceptive methods used by 
African women.2,3 During the past two decades, depo-
medroxyprogesterone acetate (DMPA), the most widely 
used injectable contraceptive method,3 has been assoc-
iated with increased risk of HIV acquisition by women in 
some but not all studies.4 A possible association between 
DMPA use and HIV risk has prompted debate over its 
safety and relative reproductive health beneﬁ ts, with 
some people calling for randomised controlled trials of 
various contraceptive methods, including DMPA.5 
Whether DMPA increases risk of other sexually 
transmitted viral infections such as herpes simplex virus 
type 2 (HSV2) is unknown.
Investigators of many observational studies have 
assessed the association between injectable and oral 
hormonal contraceptive use and HIV acquisition in 
women,4 although interpretation of results has been 
complex.5,6 In a systematic review, Polis and colleagues4 
identiﬁ ed little evidence for increased HIV risk with use 
of either oral hormonal contraception or norethisterone 
injectable hormonal contraception; however, results 
conﬂ icted as to whether DMPA was linked with HIV 
acquisition. Of seven high-quality epidemiological studies 
that reported DMPA-speciﬁ c estimates and were included 
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in the review, investigators of three noted signiﬁ cantly 
increased HIV risk,7–9 two noted non-signiﬁ cantly in-
creased risk,10,11 and two noted non-signiﬁ cantly decreased 
risk12,13 in DMPA users. A meta-analysis14 including these 
and three other studies estimated a 40% increased HIV 
risk with DMPA use for all women (pooled hazard ratio 
[HR] 1·40, 95% CI 1·16–1·69), although this risk was 
lower for women in the general population (excludes 
known high-risk women; 1·31, 1·10–1·57).
The pathophysiology of how DMPA, a progestin-only 
hormonal contraceptive method, might theoretically 
increase HIV risk is unclear. Thinning of the vaginal 
epithelium and endometrium, increased immune 
activation in the genital tract, and heightened risk of 
other sexually transmitted infections, including HSV2, 
have been postulated as mechanisms.15,16 Vaginal thinning 
after administration of DMPA has been noted in rhesus 
macaques;17,18 however, investigators of studies in women 
have found little evidence for vaginal thinning or cervical 
ectopy with DMPA use.19–21 Findings from other studies 
suggest that progestins might modulate HIV suscept-
ibility via increased expression of CCR5 co receptors on 
CD4-positive T cells and recruitment of HIV target cells 
(eg, dendritic cells) to the vaginal and stromal epithelial 
tissues.22–24
HSV2 is a common sexually transmitted virus, and its 
transmission is associated with substantial morbidity 
around the world.25,26 The worldwide burden of HSV2, like 
that of HIV, is disproportionately concentrated in 
sub-Saharan Africa.27 HSV2 infection is a frequent cause 
of genital ulcer disease,28,29 which is a risk factor for HIV.30,31 
The main HSV2 target cells in the genital tract are the 
epithelial cells, although HSV2 can infect dendritic 
cells.25,32–34 Findings from challenge studies in mice have 
shown increased HSV2 susceptibility and impaired 
immunological responses to HSV2 in the presence of 
DMPA.35,36 Despite high HIV and HSV2 co-infection,31,37 
investigators of only one epidemiological study38 have 
examined the association between use of oral or injectable 
hormonal contraception and incident HSV2 infection in 
women. The investigators found no association between 
use of injectable or oral hormonal contraceptives and 
HSV2 in HIV-negative sex workers in Kenya; however, the 
HSV2 serostatus of the women’s partners was unknown. 
In this study, we assessed whether use of DMPA or oral 
hormonal contraceptives was associated with increased 
risk of HSV2 acquisition in HIV-negative women in long-
term sexual partnerships with HIV-negative men of 
known HSV2 serostatus in Rakai, Uganda.
Methods
Study design and participants
The Rakai Health Sciences Program in Rakai, Uganda, 
enrolled HIV-negative men into a randomised trial of 
male circumcision for prevention of HIV and other 
sexually transmitted infections.39,40 Men were eligible for 
enrolment if they were HIV negative, uncircumcised, 
aged 15–49 years, and provided written informed consent. 
Research in context
Evidence before this study
We did a systematic search of PubMed with no speciﬁ ed start 
date up to Jan 23, 2015, using the following key terms: 
“hormonal”, “contraception”, “contraceptives progesterone”, 
“progestin”, “progestins”, “oral contraception”, “oral 
contraceptives”, “depo(t)medroxyprogesterone”, “depo”, 
“depot”, “DMPA”, “NET EN”, “NET-EN”, “norethisterone 
enanthate”, “medroxyprogesterone 17-acetate”, “injectable”, 
“levonorgestrel”, “etonogestrel”, “implant”, “uniplanar”, 
“jadelle”, “implanon”, “norplant”, “norplant2”, “sino-implant”, 
“contraceptives postcoital”, “emergency contraception and 
contraceptives”, “ulipristal acetate”, “Plan B”, “mifepristone”, 
“levonorgestrel intrauterine devices”, “IUD”, “IUCD”, “IUS”, 
“intrauterine system”, “intra-uterine system”, “intrauterine 
device”, “intra-uterine device”, “Mirena”, “Cyclofem”, “Lunell”, 
“Mesigyna”, “Cyclo Provera”, “Cycloprovera”, “contraceptive 
devices”, “contraceptive agents and ring”, “NuvaRing”, “Nuva 
Ring”, “contraceptive devices/agents and patch”, “Ortho Evra”, 
“Ortho-Evra”, “herpes simplex”, “herpes genitalis”, “genital 
herpes”, “herpes simplex virus infection”, “HSV”, “HSV type 2”, 
“genital herpes infection”, “herpes simplex virus type 2”, and 
“HSV2”. We identiﬁ ed only one study that assessed the relation 
between incident HSV2 infection and use of either oral or 
injectable hormonal contraception in women. Investigators of 
this study of HIV-negative sex workers in Kenya found no 
association between use of injectable or oral hormonal 
contraception and HSV2; however, the HSV2 serostatus of the 
women’s partners was unknown. Findings from challenge 
studies in mice suggest that DMPA might increase susceptibility 
to HSV2 in the genital tract.
Added value of this study
This study is the ﬁ rst prospective study to assess the relation 
between use of depo-medroxyprogesterone acetate (DMPA), 
a widely used injectable hormonal contraceptive method, and 
incident HSV2 infection in HIV-negative women with male 
partners of known HSV2 status. Despite few incident events in 
a small number of women and a long interval between annual 
study visits, we noted signiﬁ cantly increased HSV2 risk in 
women who self-reported consistently using DMPA.
Implications of all the available evidence
Taken together with previous evidence, these ﬁ ndings suggest 
that incident HSV2 might be associated with use of DMPA, 
which should be assessed in other studies with larger sample 
sizes and more frequent follow-up than in this study. Improved 
access to a wide range of highly eﬀ ective contraceptive 
methods should be a public health priority, particularly in 
sub-Saharan Africa.
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Men who had contraindications for surgery (eg, anaemia 
or active genital infection) were treated, and if their 
medical disorder resolved, they were rescreened and 
enrolled into the trial. Those with anatomical abnorm-
alities (eg, hypospadias), other medical con traindications, 
or indications for surgery (eg, severe phimosis) were 
excluded. Participants were randomly assigned to receive 
immediate male circumcision (inter vention group) or 
male circumcision delayed for 24 months (control group). 
Consenting female partners of male trial participants 
who were married or in long-term consensual relation-
ships were invited to participate in a separate follow-up 
study.41,42
The analysis in our study was restricted to HIV-negative 
and HSV2-negative women, aged 15–49 years, who were 
enrolled concurrently with their HIV-negative male 
partner. Female participants needed to have at least one 
follow-up visit at which we ascertained their HSV2 
status, and her partner’s HIV status also needed to be 
known. We excluded women if either they or their male 
partners HIV seroconverted because an association 
exists between HIV and HSV2 acquisition,30,31,43 and these 
events were too infrequent for stratiﬁ ed analyses. Women 
who self-reported use of intrauterine devices or implants 
were excluded because small numbers of these women 
limited power to detect associations between their use 
and HSV incidence.
The trials were approved by the Uganda National 
Council for Science and Technology (Kampala, Uganda), 
the Science and Ethics Committee of the Uganda Virus 
Research Institute (Entebbe, Uganda), the Committee 
for Human Research at Johns Hopkins University 
Bloomberg School of Public Health (MD, USA), and the 
Western Institutional Review Board (WA, USA).40,41 
Participants provided written informed consent, which 
included permission to use samples for future research. 
The male circumcision trial was registered with 
ClinicalTrials.gov, number NCT00425984, and the follow-
up of female partners of the male circumcision trial 
participants was also registered, number NCT00124878.
Procedures
At enrolment and two annual follow-up visits, we 
interviewed the women to ascertain sociodemographic 
characteristics, sexual risk behaviours, and health status. 
We similarly interviewed the men. We also asked the 
women about pregnancy status and intention to use and 
actual use of family planning methods, including oral, 
injectable, and implantable hormonal contraceptives. 
Because DMPA is the main injectable hormonal contra-
ceptive method available in Rakai (more than 98% of users; 
Gray RH, unpublished), we did not ask women to specify 
which form of injectable contraception that they were 
using. At each visit, we asked the men and women to 
provide blood samples, which we maintained at 4–10°C for 
less than 6 h, and then at –80°C until assayed. The primary 
study outcome was HSV2 seroconversion.
We established HSV2 infection with HSV2 ELISA 
(Kalon Biological, Guildford, UK). As previously 
described,37,39,42,44 we deﬁ ned an HSV2 seroconversion as a 
negative enrolment serology (optical density of 0·9 or 
less) followed by a positive follow-up serology (optical 
density index value of at least 1·5). We conﬁ rmed all 
incident HSV2-positive cases ascertained with ELISA 
with Euroimmun Western blot (Euroimmun, Lubeck, 
Germany).37,39,42 We established HIV status with two 
separate ELISAs and conﬁ rmed discordant results with 
an HIV1 western blot. We established HSV2 and HIV1 
infection status for the women and their partners.40
We assessed self-reported hormonal contraceptive use at 
each study visit. We treated hormonal contraceptive use as 
a time-varying exposure, and classiﬁ ed use during a given 
visit interval with report of hormonal contraceptive use at 
the present and previous study visits. We deﬁ ned 
hormonal contraceptive use during a visit interval as 
either DMPA or oral hormonal contraceptive use. We 
analysed consistency of hormonal contraceptive use in 
DMPA users. We classiﬁ ed DMPA use as consistent when 
a woman reported using DMPA at both her present and 
previous study visit. When a woman reported using 
DMPA at her present but not previous visit, we classiﬁ ed 
her as having initiated use during that interval. We 
classiﬁ ed women who self-reported using DMPA at the 
previous but not present visit as having discontinued use. 
We deﬁ ned women who were pregnant at the present or 
previous visit and who reported no hormonal contraceptive 
use—DMPA or oral hormonal contraception—as a sepa-
rate exposure group. The reference group was women 
who were neither pregnant nor using any hormonal 
contraceptive method at the present or previous study 
visit, and included women who were using condoms, 
natural family planning methods, or spermicides, or had a 
hysterectomy or tubal ligation.
Statistical analysis
We established signiﬁ cant diﬀ erences in enrolment 
demographics, sexual behaviours, and health charac-
teristics between women who ever reported oral or DMPA 
use and those who never reported hormonal contraceptive 
use using a χ² test for categorical variables and a Wilcoxon 
rank-sum test for continuous variables.
We administratively censored women who did not 
acquire HSV2 at year 2 or at loss to follow-up. We included 
all women in the primary analysis, irrespective of their 
spouse’s HSV2 status. In a separate analysis, we assessed 
the association between DMPA use and HSV2 acquisition 
in women whose male partner was HSV2 seropositive at 
her present study visit, including women whose partners 
acquired HSV2 during the same visit interval.
We calculated time at risk as the time elapsed between 
annual visits. We assumed that women who sero-
converted between visits did so at the midpoint of the 
visit interval. We calculated incidence of HSV2 per 
100 person-years. In view of the discrete nature of the 
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data (only two follow-up visits) and the large amount of 
time between annual visits, we used complementary log-
log regression models with generalised estimating 
equations and robust variance estimators to estimate 
HRs and 95% CIs. The complementary log-log model is 
a discrete time survival model and is similar to the 
continuous time Cox proportional hazards model; 
however, the discrete model assumes constant hazard 
within an interval, although the hazard can vary between 
intervals.45 We used generalised estimating equations 
and robust variance estimators to obtain population-
averaged eﬀ ect estimates and account for correlation 
between ﬁ ndings from the same woman over time.46 We 
used the complementary log-log regression models for 
all primary analyses and the sensitivity analysis that 
excluded women who self-reported condom use. We 
implemented the models using the xtcloglog command 
with the pa and robust options in Stata version 11.0.
We included variables in adjusted analyses if we either 
identiﬁ ed them as confounders in previous observational 
studies of hormonal contraceptive use and HIV 
acquisition and not as a marker of HSV2 or HIV1 
infection6 or associated them with hormonal con-
traceptive exposure and HSV2 seroconversion in the 
study population at p<0·1. Time-invariant covariates 
included age and educational status of female participants 
and their male partners, and female self-reported 
number of lifetime sexual partners at enrolment. Time-
varying confounders included male circumcision, female 
self-reported coital frequency, and female and male 
partner self-report of any condom use and non-marital 
partners in the past year. We did not include coital 
frequency or male circumcision status in the ﬁ nal 
adjusted model because they did not signiﬁ cantly alter 
the primary eﬀ ect estimates (by more than 10%) or 
improve the model likelihood in nested comparisons as 
established by the quasi-likelihood under independence 
criterion.47
Role of the funding source
The funders of the study had no role in the study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication. 
Results
Between Aug 11, 2003, and July 6, 2006, 4996 HIV-
negative men were enrolled into the trial of male 
circumcision.39,40 1638 HIV-negative female partners were 
enrolled and followed up concurrently with their male 
partners in a separate follow-up study.41,42 Of these 
women, 740 HSV2-negative and HIV-negative women 
were concurrently enrolled with their HIV-negative male 
spouse. After excluding 41 (6%) women with insuﬃ  cient 
follow-up, two (<1%) who used intrauterine devices, ﬁ ve 
(1%) who used implantable contraception, six (1%) who 
HIV seroconverted, and four (1%) whose partners HIV 
seroconverted, we included 682 (92%) women with 
660 male partners in the ﬁ nal analysis population. The 
Figure: Patterns of hormonal contraceptive use over 2 years and HSV2 incidence
(A) Individual-level patterns of hormonal contraceptive use between enrolment and year 2 study visits for a random sample of 50 hormonal contraceptive users. 
(B) Classiﬁ cation of exposure to hormonal contraception for a visit interval using contraceptive and pregnancy statuses from the present and previous study visits. 
DMPA=depo-medroxyprogesterone acetate. HC=hormonal contraception. HSV2=herpes simplex virus type 2. t–1=previous visit. t=present visit. *No woman 
switched from DMPA to oral HC.
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number of female participants exceeded that of male 
partners because of polygamous relationships. The 
number of women with male partners in the intervention 
(n=341) and control (n=341) arms of the male 
circumcision trial was equal. Female participants 
contributed 1207 person-visits to the analysis, and we 
followed them up for an average of 1·7 person-years. 
Retention was 95% at year 1 (650 participants) and 82% 
at year 2 (557 participants). Follow-up between year 1 and 
year 2 did not signiﬁ cantly diﬀ er between oral hormonal 
contraceptive users (16 [84%] of 19), DMPA users 
(consistent use 21 [72%] of 29; initiated use 44 [83%] of 
53; discontinued use 18 [67%] of 27), or pregnant women 
(206 [84%] of 244) when we compared these groups with 
women who were neither pregnant nor using hormonal 
contraception (232 [78%] of 296). 
173 (25%) of 682 women self-reported ever using 
hormonal contraception at enrolment or at a follow-up 
visit. Of these women using hormonal contraception, 
147 (85%) reported DMPA use only, 22 (13%) reported oral 
hormonal contraceptive use only, and four (2%) reported 
DMPA and oral use at diﬀ erent study visits. 129 (85%) of 
151 women initiated (99 [66%]) or discontinued (52 [34%]) 
DMPA use during the study (ﬁ gure). Only 57 (38%) of 
151 women consistently reported DMPA use at successive 
visits. Pregnancy was common—338 (50%) of female 
participants fell pregnant at either enrolment (163 [24%]) or 
a follow-up visit (218 [32%]).
Table 1 shows participant characteristics at enrolment, 
broken down by contraceptive use. For all women, the 
median age of female participants was 24 years 
(IQR 21–28) and the median age of their male partners 
was 28 years (IQR 24–32). Only 112 (16%) of women 
reported using condoms at enrolment. Self-report of 
extramarital partners was 19 (3%) among women and 
225 (33%) in men. We noted some diﬀ erences in 
enrolment charac teristics between women who did and 
did not use DMPA or oral hormonal contraception. 
Women who reported DMPA use were slightly older and 
less likely to be pregnant than were those who reported 
no hormonal contraceptive use, and women who either 
reported DMPA or oral hormonal contraceptive use were 
slightly more educated than were those who reported no 
hormonal contraceptive use. Their male partners were 
also slightly more educated if their female partner had 
either reported DMPA or oral hormonal contraceptive 
use, and slightly more likely to report using condoms in 
the past year if their female partner had reported DMPA 
use than were those whose female partner had reported 
no hormonal contraceptive use. At enrolment, both 
DMPA and oral hormonal con traceptive users and non-
users had similar proportions of HSV2-seropositive 
partners, self-reported condom use, and self-reported 
genital ulcer disease. Male partners of DMPA and oral 
hormonal contraceptive users and non-users also had 
similar self-reported genital ulcer disease and assignment 
to the intervention arm of the male circumcision trial. 
26 (4%) women reported using DMPA or oral hormonal 
contraception at the start of a visit interval and were then 
found to be pregnant at their next visit (ﬁ gure). 16 of these 
women reported planning to become pregnant during 
the interval. Of those who had an unplanned pregnancy 
No HC Any oral HC* p value† Any DMPA* p value†
Overall (n=682)
n (%) 509 (75%) 26 (4%) ·· 151 (22%) ··
Demographics at enrolment
Female age (years) 24 (21–27) 25 (21–27) 0·874 25 (22–29) 0·023
Male partner’s age (years) 27 (24–32) 30 (25–33) 0·633 29 (25–33) 0·085
Polygamous male partner 55 (11%) 4 (15%) 0·467 19 (13%) 0·543
Female education status
None 67 (13%) 2 (8%) 13 (9%)
Primary 379 (74%) 16 (62%) 98 (65%)
Secondary 57 (11%) 6 (23%) 30 (20%)
Postsecondary 6 (1%) 2 (8%) 0·011 10 (7%) <0·0001
Male partner’s educational status
None 51 (10%) 1 (4%) 6 (4%)
Primary 374 (73%) 12 (46%) 97 (64%)
Secondary 65 (13%) 8 (31%) 29 (19%)
Postsecondary 19 (4%) 5 (19%) <0·0001 19 (13%) <0·0001
Sexual behaviours at enrolment
Female lifetime sexual partners
One 234 (46%) 9 (35%) 61 (40%)
Two 177 (35%) 9 (35%) 53 (35%)
Three 65 (13%) 5 (19%) 23 (15%)
Four or more 33 (6%) 3 (12%) 0·488 14 (9%) 0·455
Non-marital relationships in 
the past year
17 (3%) 0 0·344 2 (1%) 0·193
Condom use in the past year‡ 79 (16%) 4 (15%) 0·978 30 (20%) 0·214
Male partner sexual behaviours at enrolment
Non-marital relationships in 
the past year
163 (32%) 5 (19%) 0·170 58 (38%) 0·144
Condom use in the past year‡ 159 (31%) 6 (23%) 0·379 68 (45%) 0·002
Health characteristics
Ever pregnant during study 269 (53%) 11 (42%) 0·294 61 (40%) 0·007
Female self-reported GUD at 
enrolment
42 (8%) 0 0·127 12 (8%) 0·905
Male partner self-reported 
GUD at enrolment
23 (5%) 0 0·268 8 (5%) 0·691
Male partner in trial 
intervention group
256 (50%) 14 (54%) 0·724 73 (48%) 0·674
Male partner’s HSV2 status at enrolment
Negative 366 (72%) 21 (81%) 116 (77%)
Indeterminate 61 (12%) 2 (8%) 12 (8%)
Positive 80 (16%) 3 (12%) 22 (15%)
Unknown 2 (<1%) 0 0·792 1 (1%) 0·496
Data are n (%) or median (IQR). HC=hormonal contraception. DMPA=depo-medroxyprogesterone acetate. 
GUD=genital ulcer disease. HSV2=herpes simplex virus 2. *Four women self-reported using oral HC and DMPA during 
the study (not at same visits). The four women are included in both groups—women using any oral HC and women 
using any DMPA. †Wilcoxon rank-sum p values for continuous variables and χ² p values for categorical variables 
(compared with non-HC users). ‡214 (98%) of 218 women reporting condom use at enrolment or follow-up reported 
consistent condom use during sexual intercourse. 
Table 1: Baseline characteristics
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(ten), one reported using oral hormonal contraception at 
the time that she became pregnant and one reported 
using DMPA. The remaining eight reported using no 
form of contraception. When a woman became pregnant 
and was not using hormonal contraception at her 
previous visit (199 [16%] of 1207), 108 (54%) of these 
pregnancies were reported as unplanned. Of these 
women, none reported using hormonal contraception—
DMPA or oral hormonal contraception—at the time that 
they became pregnant.
As shown in table 2, we noted incident HSV2 infections 
in 70 (10%) women (primary outcome). 39 (56%) 
infections occurred in women with HSV2-seronegative 
male partners, 23 (33%) occurred in women with HSV2-
seropositive partners, and eight (11%) occurred in women 
who had partners of unknown or indeterminate HSV2 
status. 13 (19%) women who seroconverted reported 
genital ulcers in the past year (HR 2·2, 95% CI 1·2–4·0). 
Overall, HSV2 incidence was 5·8 per 100 person-years. 
We noted no increased risk of HSV2 acquisition during 
Incident 
infections/py
Incidence per 
100 py
Unadjusted HR p value Adjusted HR p value
HC use status
No HC use, not pregnant 35/529·5 6·6 1·00 ·· 1·00 ··
No HC use, pregnant 18/423·5 4·3 0·64 (0·36–1·12) 0·119 0·66 (0·37–1·19) 0·169
Oral HC use 1/35·5 2·8 0·44 (0·06–3·22) 0·418 0·49 (0·08–3·01) 0·441
DMPA use
Discontinued use 2/51·0 3·9 0·57 (0·14–2·37) 0·437 0·58 (0·13–2·51) 0·535
Initiated use 5/96·5 5·2 0·75 (0·30–1·92) 0·554 0·75 (0·29–1·92) 0·632
Consistent use 9/66·5 13·5 2·02 (0·96–4·26) 0·066 2·26 (1·09–4·69) 0·029
Age (years)*
Male partner ·· ·· 0·95 (0·90–1·00) 0·043 0·95 (0·86–1·04) 0·247
Female participant ·· ·· 0·98 (0·94–1·03) 0·400 1·00 (0·92–1·09) 0·992
Female educational status
None 5/151·5 3·3 0·49 (0·20–1·21) 0·165 0·66 (0·29–1·50) 0·323
Primary 58/88·5 6·8 1·00 ·· 1·00 ··
Secondary 6/164·0 3·7 0·55 (0·24–1·28) 0·165 0·41 (0·16–1·05) 0·065
Postsecondary 1/31·5 3·2 0·50 (0·07–3·49) 0·488 0·15 (0·02–1·27) 0·083
Male educational status
None 4/104·0 3·8 0·82 (0·29–2·30) 0·688 1·09 (0·39–3·11) 0·863
Primary 42/854·5 4·9 1·00 ·· 1·00 ··
Secondary 18/171·0 10·5 2·19 (1·26–3·81) 0·005 1·92 (1·09–3·41) 0·024
Postsecondary 6/73·0 8·2 1·71 (0·74–3·97) 0·212 2·85 (1·13–7·18) 0·026
Female lifetime sexual partners
One 24/549·0 4·4 1·00 ·· 1·00 ··
Two 22/415·5 5·3 1·23 (0·69–2·20) 0·486 1·27 (0·71–2·29) 0·414
Three 11/161·5 6·8 1·58 (0·77–3·26) 0·212 1·41 (0·66–3·01) 0·371
Four or more 13/76·5 17·0 3·99 (2·03–7·82) <0·001 3·45 (1·72–6·92) <0·0001
Female non-marital relationships
No 65/1162·0 5·6 1·00 ·· 1·00 ··
Yes 5/40·5 12·3 2·26(0·96–5·29) 0·062 1·28 (0·46–3·58) 0·633
Male non-marital relationships
No 46/918·5 5·0 1·00 ·· 1·00 ··
Yes 24/284·0 8·5 1·68 (1·03–2·76) 0·039 1·08 (0·61–1·90) 0·802
Female condom use
No 54/973·0 5·6 1·00 ·· 1·00 ··
Yes 16/216·5 7·4 1·33 (0·77–2·33) 0·337 0·89 (0·49–1·63) 0·715
Male condom use
No 36/822·5 4·4 1·00 ·· 1·00 ··
Yes 33/371·5 8·9 2·00 (1·25–3·21) 0·004 1·70 (0·98–2·97) 0·060
Data are n/py or HR (95% CI). py=person-years. HR=hazard ratio. HC=hormonal contraception. DMPA=depo-medroxyprogesterone acetate. *We treated age as a 
conterminous variable in this model.
Table 2: Risk factors for incident HSV2 infection
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pregnancy (adjusted HR 0·66, 95% CI 0·37–1·19) or in 
oral hormonal contraceptive users (0·49, 0·08–3·01). 
Risk of HSV2 was signiﬁ cantly increased in women 
consistently using DMPA (2·26, 1·09–4·69; p=0·029); 
however, we did not note heightened risk in those who 
recently initiated or discontinued DMPA use (table 2). In 
a sensitivity analysis, results were similar in women who 
never reported condom use (appendix).
Other factors that were signiﬁ cantly associated with 
female HSV2 seroconversion after adjustment included 
an increased number of female lifetime sexual partners 
at enrolment and increased male partner’s educational 
status (table 2). Few women reported non-marital 
relationships during follow-up (35 [5%] of 682). Of the 
HSV2-seroconverting women who had HSV2-sero-
negative partners, two (5%) of 39 reported non-marital 
relationships during the interval between the last 
negative and ﬁ rst positive visits.
132 (19%) women had an HSV2-seropositive spouse at 
enrolment or follow-up. Of these women, 27 (20%) had 
partners who HSV2 seroconverted after enrolment, 
including six (5%) HSV2-incident women whose spouses 
seroconverted during the same visit interval. The rate of 
female HSV2 acquisition was 10·6 per 100 person-years 
(23 per 218 person-years) in women with an HSV2-
infected partner, which was signiﬁ cantly higher than was 
incidence in women with an HSV2-negative partner 
(4·8 per 100 person-years; 39 per 814·5 person-years; 
p=0·001). Incidence of HSV2 in women with HSV2-
infected partners is shown in table 3. The increased risk 
of incident HSV2 in consistent DMPA users with HSV2-
infected partners was statistically signiﬁ cant. 
Discussion
Consistent use of DMPA was associated with a greater 
than two times increased risk of HSV2 seroconversion 
compared with no hormonal contraceptive use. In an 
analysis restricted to women with known exposure to 
HSV2-seropositive partners, the risk of incident HSV2 
with consistent DMPA use was more than six times 
greater than with no hormonal contraceptive use. 
Pregnancy was common, with half of women falling 
pregnant during the 2 year follow-up, predominately in 
those not using any form of contraception. Investigators 
of some, but not all, observational studies have noted 
increased risk of HIV during pregnancy,48 including one 
prospective study in Rakai.49 We noted no such analogous 
risk of HSV2 acquisition during pregnancy in this study.
Most women who reported using a hormonal contra-
ceptive method used DMPA, and DMPA use was highly 
dynamic. DMPA use has been associated with HIV 
acquisition in several studies, including a meta-analysis,14 
but the data are inconsistent. Two studies assessed the 
association between DMPA use and HIV in Rakai;50,51 
however, investigators of both noted no signiﬁ cantly 
increased HIV risk in DMPA users. By contrast with 
DMPA, little evidence exists that oral hormonal 
contra ceptive methods augment HIV risk.4 We had very 
low power to detect an association between oral hormonal 
contraceptive use and HSV2 acquisition, although our 
results suggest that risk of HSV2 acquisition is not 
increased in oral hormonal contraceptive users.
We cannot rule out the possibility that unmeasured or 
poorly measured behaviours, or other factors associated 
with DMPA use and a cause of HSV2 infection, could have 
confounded our results.6 For example, if women with high-
risk sexual behaviours were more likely to use DMPA but 
these behaviours were not reported accurately, the ﬁ ndings 
could be biased. Indeed, women substantially under-
reported extramarital partnerships, as evidenced by half of 
all HSV2 infections occurring in women who reported no 
external relationships but had HSV2-seronegative 
partners. However, we still noted an assoc iation between 
DMPA and incident HSV2 when we restricted analyses to 
those women with known HSV2-infected partners only. 
Consistent condom use can reduce HIV acquisition by 
80%;52 however, ﬁ ndings from meta-analyses53 suggest 
that condom eﬀ ectiveness is only 30% for HSV2 
acquisition. This decreased eﬀ ectiveness is because 
HSV2 can be transmitted to and from genital areas that 
are not protected by male condoms.25 Although condoms 
have been identiﬁ ed as important time-dependent con-
founders in observational studies of HIV and hormonal 
contraceptive use,6 we noted no association between 
female reported condom use and HSV2 acquisition. We 
also noted no signiﬁ cant diﬀ erences in our eﬀ ect 
estimates in a sensitivity analysis excluding women who 
ever reported using condoms.
This study has other limitations. Information about 
contraceptive exposures was based on self-reported use of 
DMPA or oral hormonal contraceptive use at the time of 
a study visit, and we inferred consistency of DMPA use by 
reported use at successive visits. The trial from which we 
derived these data was not designed to assess associations 
between contraception and HSV2 acquisition, and the 
interval between follow-up visits (1 year) cannot accurately 
assess the timing of HSV2 acquisition in relation to 
Incident 
infections/py
Incidence 
per 100 py
Unadjusted HR p value Adjusted HR p value
No HC use, not 
pregnant
11/103·0 10·7 1·00 ·· 1·00 ··
No HC use, pregnant 3/71·5 4·2 0·38 (0·11–1·35) 0·133 0·27 (0·06–1·13) 0·075
Oral HC use 0/6·0 ·· ·· ·· ·· ··
DMPA use
Discontinued use 1/7·5 13·3 1·19 (0·16–9·01) 0·863 2·42 (0·29–20·1) 0·411
Initiated use 4/19·0 21·1 1·86 (0·59–5·78) 0·283 1·42 (0·25–8·08) 0·691
Consistent use 4/11·0 36·4 3·31 (0·99–11·0) 0·051 6·23 (1·49–26·3) 0·012
Data are n/py or HR (95% CI). Analysis included six women whose partners also herpes simplex virus 2 seroconverted 
during the same visit interval; one of these women was consistently using DMPA. py=person-years. HR=hazard ratio. 
HC=hormonal contraception. DMPA=depo-medroxyprogesterone acetate. 
Table 3: Association between hormonal contraceptive use and HSV2 acquisition in HIV-negative women 
with HSV2-seropositive partners
See Online for appendix
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contraceptive exposures. The long follow-up intervals 
could also aﬀ ect women’s recall of their risk behaviours. 
However, the prospective design, laboratory methods, 
and inclusion of information about both women and 
their stable male partners were study strengths. Notably, 
the main ﬁ nding of increased risk of HSV2 seroconversion 
with consistent DMPA use was based on only nine 
incident cases and the CIs around the point hazards 
estimate are wide. Nevertheless, other studies of HIV 
acquisition and injectable contraception were also based 
on similarly small numbers of seroconversions.54
The ﬁ nding that consistent use of DMPA might 
increase women’s risk of HSV2 acquisition might be 
relevant to the associations between HIV risk and use of 
DMPA in some previous studies,4 and might show that 
DMPA broadly aﬀ ects the risk of viral sexually transmitted 
infections. However, these results are based on only a 
small number of cases and need to be substantiated in 
other populations with more frequent follow-up than in 
this study and validated contraceptive exposure histories. 
Future randomised trials of hormonal contraceptives 
should assess incidence of HSV2 in addition to HIV as 
potential study outcomes.5 The possibility of an increased 
risk of HIV and HSV2 associated with DMPA use should 
be weighed against its beneﬁ ts, including reduced risk of 
maternal mortality and unwanted pregnancy. Increased 
access to other forms of highly eﬀ ective, long-acting, low-
dose contraceptive methods, including intrauterine 
devices and implants, is needed in sub-Saharan Africa.
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